Abnormalities, Multiple: Clinical Trials

17 trials for Abnormalities, Multiple, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 active not recruiting. 17 Phase 2, 3 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 217Active not recruiting 17
Phase 13Active not recruiting 3
Phase 32Active not recruiting 2

Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
VX-407 - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2Active not recruitingVertex Pharmaceuticals Incorporated262025-11-192026-09-21
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Setmelanotide - Prader-Willi Syndrome, Obesity
Phase 2Active not recruitingRhythm Pharmaceuticals, Inc.182025-03-042026-11-13
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention - Retinitis Pigmentosa (RP), Usher Syndrome Type 2
Phase 2Active not recruitingLaboratoires Thea812024-12-112026-07-09
Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
AAVB-081 - Usher Syndrome, Type 1B
Phase 1 / Phase 2Active not recruitingAAVantgarde Bio Srl152024-07-022026-11-18
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718 - Hypothalamic Obesity, Prader-Willi Syndrome
Phase 1 / Phase 2Active not recruitingRhythm Pharmaceuticals, Inc.1112024-03-052026-10-09
Study of Tamibarotene in Patients With ADPKD
Tamibarotene, Placebo - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2Active not recruitingRege Nephro Co., Ltd.702023-12-222025-04-04
Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
Atomoxetine and Oxybutynin (ato-oxy) - Obstructive Sleep Apnea, Down Syndrome
Phase 2Active not recruitingUniversity of Arizona362023-09-292026-04-07
AMX0035 in Adult Patients With Wolfram Syndrome
AMX0035 - Wolfram Syndrome
Phase 2Active not recruitingAmylyx Pharmaceuticals Inc.122023-03-032026-04-14
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
Empagliflozin, Placebo - Polycystic Kidney, Autosomal Dominant
Phase 2Active not recruitingUniversity of Colorado, Denver502022-11-182026-05-01
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
CAM2029, Placebo - Polycystic Liver Disease
Phase 2 / Phase 3Active not recruitingCamurus AB712022-06-282026-06-01
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome
Phase 2 / Phase 3Active not recruitingQuoin Pharmaceuticals302022-06-232026-03-16
MK-7075 (Miransertib) in Proteus Syndrome
MK-7075 (miransertib) - Proteus Syndrome
Phase 2Active not recruitingNational Human Genome Research Institute (NHGRI)382022-05-202026-07-17
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
ION582 - Angelman Syndrome
Phase 1 / Phase 2Active not recruitingIonis Pharmaceuticals, Inc.712021-12-222026-11-17
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
Belzutifan - VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation
Phase 2Active not recruitingPeloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)502018-05-022026-04-13
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
Daunorubicin, Prednisolone, Vincristine - Down Syndrome, Acute Lymphoblastic Leukemia
Phase 2Active not recruitingNational Hospital Organization Nagoya Medical Center602017-04-182026-05-11
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen - Mucopolysaccharidosis Disorders, Hurler Syndrome
Phase 2Active not recruitingMasonic Cancer Center, University of Minnesota1492014-07-102026-11-03
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
Blood draw for the laboratory assessment - Usher's Syndrome
Phase 2Active not recruitingSanofi92013-09-122026-01-13

Narrower conditions

Polycystic Kidney, Autosomal Dominant (4)  ·  Usher Syndromes (3)  ·  Down Syndrome (2)  ·  Obesity (2)  ·  Prader-Willi Syndrome (2)  ·  Retinitis Pigmentosa (2)  ·  Alpha-Methylacyl-CoA Racemase Deficiency (1)  ·  Angelman Syndrome (1)  ·  Aspartylglucosaminuria (1)  ·  Eye Abnormalities (1)  ·  Eye Diseases, Hereditary (1)  ·  Fucosidosis (1)  ·  Hereditary Diffuse Leukoencephalopathy with Spheroids (1)  ·  Hyperphagia (1)  ·  Leukodystrophy, Globoid Cell (1)

Broader conditions

Congenital Abnormalities (17)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17)  ·  Genetic Diseases, Inborn (16)  ·  Nervous System Diseases (11)  ·  Neurologic Manifestations (9)  ·  Female Urogenital Diseases (7)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Male Urogenital Diseases (7)  ·  Urogenital Diseases (7)  ·  Kidney Diseases (6)  ·  Urologic Diseases (6)  ·  Chromosome Disorders (5)  ·  Ciliopathies (5)  ·  Intellectual Disability (5)

Interventions

4-phenylbutyric acid (1)  ·  Atomoxetine Hydrochloride (1)  ·  Blood Specimen Collection (1)  ·  Cyclophosphamide (1)  ·  Cytarabine (1)  ·  Daunorubicin (1)  ·  Epirubicin (1)  ·  Hydrocortisone (1)  ·  Mercaptopurine (1)  ·  Methotrexate (1)  ·  Miransertib (1)  ·  Prednisolone (1)  ·  Regimen B (1)  ·  Stem Cell Transplantation (1)  ·  Vincristine (1)

Sponsors

Rhythm Pharmaceuticals, Inc. (2)  ·  AAVantgarde Bio Srl (1)  ·  Amylyx Pharmaceuticals Inc. (1)  ·  Camurus AB (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  Laboratoires Thea (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  National Hospital Organization Nagoya Medical Center (1)  ·  National Human Genome Research Institute (NHGRI) (1)  ·  Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Quoin Pharmaceuticals (1)  ·  Rege Nephro Co., Ltd. (1)  ·  Sanofi (1)  ·  University of Arizona (1)  ·  University of Colorado, Denver (1)

Countries

United States (14)  ·  France (5)  ·  United Kingdom (5)  ·  Belgium (3)  ·  Germany (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Canada (2)  ·  Denmark (2)  ·  Japan (2)  ·  Australia (1)  ·  Brazil (1)  ·  Hong Kong (1)  ·  Israel (1)  ·  Malaysia (1)

Top investigators

Allen Yeoh, MBBS (1)  ·  Camille Bedrosian, MD (1)  ·  David Meeker (1)  ·  David Meeker, MD (1)  ·  Joost Drenth, MD (1)  ·  Leslie G Biesecker, M.D. (1)  ·  Michel B Chonchol, MD (1)  ·  Paul Orchard, M.D. (1)  ·  Tony Andrasfay (1)

Results publications

PMID 39356039, PMID 34818478, PMID 38010035, PMID 39284337, PMID 40228516, PMID 40339601, PMID 40377984, PMID 41385299, PMID 42224880

NIH funding

2018 (1), 2023 (1), R01DK131755 (1), R33HL151254 (1)